Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India.
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
19 Nov 2021
19 Nov 2021
Historique:
pubmed:
15
10
2021
medline:
30
11
2021
entrez:
14
10
2021
Statut:
ppublish
Résumé
Delhi, the national capital of India, experienced multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks in 2020 and reached population seropositivity of >50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant, B.1.617.2 (Delta), replaced B.1.1.7 (Alpha). A Bayesian model explains the growth advantage of Delta through a combination of increased transmissibility and reduced sensitivity to immune responses generated against earlier variants (median estimates: 1.5-fold greater transmissibility and 20% reduction in sensitivity). Seropositivity of an employee and family cohort increased from 42% to 87.5% between March and July 2021, with 27% reinfections, as judged by increased antibody concentration after a previous decline. The likely high transmissibility and partial evasion of immunity by the Delta variant contributed to an overwhelming surge in Delhi.
Identifiants
pubmed: 34648303
doi: 10.1126/science.abj9932
pmc: PMC7612010
mid: EMS137316
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
995-999Subventions
Organisme : Wellcome Trust
ID : 108082
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V038109/1
Pays : United Kingdom
Références
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
EClinicalMedicine. 2021 Jul 31;39:101064
pubmed: 34401689
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Int J Infect Dis. 2021 Jul;108:145-155
pubmed: 34022338
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Epidemiol Infect. 2020 Sep 11;148:e207
pubmed: 32912354
Virus Evol. 2018 Jan 08;4(1):vex042
pubmed: 29340210
BMC Infect Dis. 2021 Jun 7;21(1):533
pubmed: 34098885
Elife. 2020 Sep 07;9:
pubmed: 32894217
BMJ Open. 2021 Jan 20;11(1):e042584
pubmed: 33472784
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
BMC Med. 2021 Apr 27;19(1):106
pubmed: 33902581
Curr Protoc Bioinformatics. 2020 Mar;69(1):e96
pubmed: 32162851
Elife. 2021 Apr 20;10:
pubmed: 33876727
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Nat Commun. 2020 Dec 3;11(1):6189
pubmed: 33273462
Science. 2021 Jul 16;373(6552):
pubmed: 34083451
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Science. 2021 Nov 19;374(6570):995-999
pubmed: 34648303
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):48-60
pubmed: 32952144
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508